Abstract
Objective: To assess the cost effectiveness of primary prophylaxis with clotting factor instead of treatment following a bleed (on-demand) for individuals with severe haemophilia.
Design: Different data sources on the clinical effects and costs of treatments were combined using a Markov model.
Setting: English treatment centres.
Perspective: UK societal.
Participants: Hypothetical cohorts of 100 individuals with severe haemophilia A or B or severe von Willebrands disease.
Interventions: Primary prophylaxis treatment on-demand with clotting factor.
Outcome measures: Costs, quality-adjusted life-years (QALYs) and incremental cost per QALY in UK pounds (£, 1999/2000 values).
Results: The baseline results showed that treating individuals with severe haemophilia A/severe von Willebrands disease or severe haemophilia B with primary prophylaxis instead of treatment on-demand cost an additional £46 500 and £8600 per QALY gained, respectively. However, the results were extremely sensitive to a number of factors including the clotting factor unit cost, the time between prophylactic doses and the discount rate.
Conclusions: Despite the high costs of treatment, primary prophylaxis was cost effective compared with treatment on-demand in some scenarios. Primary prophylaxis is more likely to be cost effective for individuals with severe haemophilia B compared with individuals with severe haemophilia A/severe von Willebrands disease. Further research is required to assess the relationship between methods of clotting factor infusion and health-related quality-of-life.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Fig1.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Tab1.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Tab2.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Tab3.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Tab4.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Tab5.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Fig2.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00019053-200220110-00005/MediaObjects/40273_2012_20110759_Fig3.jpg)
Similar content being viewed by others
References
Nilsson IM. Hemophilia. Stockholm: Pharmacia Plasma Products, 1994
Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980; 149: 153–9
Pettersson H, Nilsson IM, Hedner U, et al. Radiological evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70 (4): 565–70
Bohn RL, Avorn J, Glynn RJ, et al. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79 (5): 932–7
Miners AH, Sabin CA, Tolley KH, et al. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand’s disease. J Intern Med 1998; 244 (6): 515–22
Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129 (3): 424–31
Szucs TD, Öffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996; 2: 211–7
Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3 (4): 419–58
Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
Williams A. Economics of coronary artery bypass grafting. BMJ 1985; 291 (6491): 326–9
Triemstra AHM, Smit C, Van der Ploeg HM, et al. Mortality in patients with hemophilia. Ann Intern Med 1995; 123: 823–7
Office for National Statistics. Age specific death rates by gender, 1996. London: HMSO, 1998
Seagroatt V, Tan HS, Goldacre M, et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991; 303 (6815): 1431–5
Miners AH, Sabin CA, Tolley KH, et al. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Intern Med 2000; 247: 493–9
Miners AH, Sabin CA, Tolley KH, et al. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378–85
Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316 (7133): 736–41
Laupacis A, Bourne R, Rorabeck C, et al. The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am 1993; 75 (11): 1619–26
Allain JP. Dose requirement for replacement therapy in hemophilia A. Thromb Haemost 1979; 42 (3): 825–31
Lofqvist T, Nilsson IM, Berntorp E, et al. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997; 241 (5): 395–400
Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (1): 25–32
UK Haemophilia Centre Directors Organization Executive Committee. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia 1997; 3: 63–77
Carlsson M, Bjorkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83–8
Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 1 Suppl. 1: 8–13
Fitzpatrick R, Shortall E, Sculpher M, et al. Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technology Assessment Report 1998; 2 (20)
Office for National Statistics. New earnings survey. London: HMSO, 1998
White A, Nicolass G, Foster K, et al. Health survey for England 1991. London: HMSO, 1993
Stevens A, Colin-Jones D, Gabbay J. ’Quick and clean’: authoritative health technology assessment for local health care contracting. Health Trends 1995; 27 (2): 37–42
Szucs TD, Offner A, Kroner B, et al. Resource utilisation in haemophiliacs treated in Europe: results from the European study on socioeconomic aspects of haemophilia care. The European Socioeconomic Study Group. Haemophilia 1998; 4 (4): 498–501
Aledort LM. Hemophilia: yesterday, today, and tomorrow. Mount Sinai J Med 1996; 63 (3–4): 225–35
Aledort LM, Bohn RL. Prophylaxis and continuous infusion for hemophilia: can we afford it? Blood Coagul Fibrinolysis 1996; 7 Suppl. 1: S35–7
Bátorová A, Martinowitz U, Makai F, et al. Adjusted dose continuous infusion of F VIII is superior to intermittent bolus therapy for major surgery in hemophilia A [abstract]. Haemophilia 1998; 4: 182
Bátorová A, Makai F, Kopác C, et al. Continuous infusion of recombinant factor VIII (KogenateR) for surgery in hemophilia A [abstract]. Haemophilia 1998; 4: 36
Bona RD, Weinstein RA, Weisman SJ, et al. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol 1989; 32 (1): 8–13
Campbell PJ, Rickard KA. Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience. Aust N Z J Med 1998; 28 (4): 440–5
Dasani H, Jones JAH, Loran C, et al. Effective haemostasis with mononine factor IX continuous infusion for two major surgeries and one large thigh haematoma in three patients with haemophilia B [abstract]. Haemophilia 1998; 4: 184
Doughty HA, Coles J, Parmar K, et al. The successful removal of a bleeding intracranial tumour in a severe haemophiliac using an adjusted dose continuous infusion of monoclonal factor VIII. Blood Coagul Fibrinolysis 1995; 6 (1): 31–4
Hathaway WE, Christian MJ, Clarke SL, et al. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984; 17: 85–8
Hay CR, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and major bleeding. Blood Coagul Fibrinolysis 1996; 7 Suppl. 1: S15–9
Ljung RCR. Prophylactic treatment in Sweden: overtreatment or optimal model? Haemophilia 1998; 4 (4): 409–12
Löfqvist T, Nilsson IM, Petersson C. Orthopaedic surgery in hemophilia: 20 years’ experience in Sweden. Clin Orthop 1996; 332: 232–41
Manco-Johnson MJ. Family issues in continuous infusion therapy with factor VIII. Blood Coagul Fibrinolysis 1996; 7 Suppl. 1: S21–5
Martinowitz U, Schulman S, Gitel S, et al. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82 (4): 729–34
Martinowitz UP, Schulman S. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Acta Haematol 1995; 94 Suppl. 1: 35–42
McMillan CW, Webster WP, Roberts HR, et al. Continuous intravenous infusion of factor VIII in classic haemophilia. Br J Haematol 1970; 18 (6): 659–67
Morfini M, Messori A, Longo G. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion. Blood Coagul Fibrinolysis 1996; 7 Suppl. 1: S11–4
Richardson NGB, Miller AL, O’shaughnessy DF. Successful treatment of acute subdural haemorrhage with continuous intravenous infusion of factor VIII on a 17 year old with haemophilia A [letter]. Haemophilia 1996; 2 (173): 176
Rochat C, McFadyen ML, Schwyzer R, et al. Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. Haemophilia 1999; 5: 181–6
Schulman S, Gitel S, Zivelin A, et al. The feasibility of using concentrates containing factor IX for continuous infusion. Haemophilia 1995; 1: 103–10
Schulman S, Martinowitz U. Continuous infusion instead of bolus injections of factor concentrate? Haemophilia 1996; 2: 189–91
Schulman S, Smith O, Wallensten R, et al. Continuous infusion of factor IX for surgery with a chemically treated and virus treated filtered concentrate (Nanotiv) [abstract]. Haemophilia 1998; 4: 182
Schulman S, Wallensten R, White B, et al. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia 1999; 5: 96–100
Tengborn L, Berntorp E. Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B. Haemophilia 1998; 4 (1): 56–9
Varon D, Schulman S, Beshari D, et al. Home therapy with continuous infusion of factor VIII after minor surgery or serious haemorrhage. Haemophilia 1996; 2: 207–10
Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. Haemophilia 1998; 4 (4): 431–5
Collins PW, Khair KS, Liesner R, et al. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br J Haematol 1997; 99 (1): 206–8
Liesner RJ, Vora AJ, Hann IM, et al. Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995; 91 (1): 203–7
Miller K, Buchanan GR, Zappa S, et al. Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr 1998; 132 (6): 934–8
Ragni MV, Hord JD, Blatt J. Central venous catheter infection in haemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate. Haemophilia 1997; 3: 90–5
Santagostino E, Gringeri A, Muca-Perja M, et al. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102 (5): 1224–8
van den Berg HM, Fischer K, Roosendaal G, et al. The use of the Port-A-Cath in children with haemophilia: a review. Haemophilia 1998; 4 (4): 418–20
Vidler V, Richards M, Vora A. Central venous catheter-associated thrombosis in severe haemophilia. Br J Haematol 1999; 104: 461–4
Warrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia 1997; 3: 194–8
Acknowledgements
The authors would like to thank Martin Buxton for comments on an earlier draft of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miners, A.H., Sabin, C.A., Tolley, K.H. et al. Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia. Pharmacoeconomics 20, 759–774 (2002). https://doi.org/10.2165/00019053-200220110-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200220110-00005